Protocol Ledger

NCT03712787 · Phase II · TERMINATED

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

Interventional Phase II clinical trial protocol NCT03712787 sponsored by AbbVie in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-03-22 Enrollment: 364 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03712787
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)364 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03712787
Protocol FieldVerified Registry Value
NCT IdentifierNCT03712787
Consolidated Lead SponsorAbbVie
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment364 participants (ACTUAL)
Registered Start Date2019-03-22
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI